S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:SNSE

Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis

$1.05
-0.04 (-3.67%)
(As of 03/28/2024 ET)
Today's Range
$1.05
$1.12
50-Day Range
$0.75
$1.17
52-Week Range
$0.51
$1.93
Volume
16,942 shs
Average Volume
85,433 shs
Market Capitalization
$26.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Sensei Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
281.0% Upside
$4.00 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.10) to ($1.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.56 out of 5 stars

Medical Sector

108th out of 939 stocks

Pharmaceutical Preparations Industry

42nd out of 443 stocks

SNSE stock logo

About Sensei Biotherapeutics Stock (NASDAQ:SNSE)

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

SNSE Stock Price History

SNSE Stock News Headlines

Sensei Biotherapeutics (NASDAQ:SNSE) Shares Up 1.9%
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Sensei Biotherapeutics to Present at Upcoming Conferences
SNSE - Sensei Biotherapeutics, Inc.
See More Headlines
Receive SNSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SNSE
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+281.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-34,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.60 per share

Miscellaneous

Free Float
18,678,000
Market Cap
$26.32 million
Optionable
Not Optionable
Beta
0.10
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. John K. Celebi M.B.A. (Age 52)
    President, CEO & Director
    Comp: $799.69k
  • Ms. Erin Colgan (Age 43)
    Chief Financial Officer
    Comp: $558.83k
  • Dr. Edward Van der Horst Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $444.87k
  • Ms. Lora Pike
    Vice President of Investor Relations & Communications
  • Mr. Christopher W. Gerry J.D.
    Senior VP, General Counsel & Secretary
  • Ms. Stephanie Krebs M.B.A.
    M.S., Chief Business Officer
  • Dr. Aaron Weitzman FACP
    M.D., Ph.D., Chief Medical Officer

SNSE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sensei Biotherapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SNSE shares.
View SNSE analyst ratings
or view top-rated stocks.

What is Sensei Biotherapeutics' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for Sensei Biotherapeutics' stock. Their SNSE share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 281.0% from the stock's current price.
View analysts price targets for SNSE
or view top-rated stocks among Wall Street analysts.

How have SNSE shares performed in 2024?

Sensei Biotherapeutics' stock was trading at $0.6920 at the start of the year. Since then, SNSE stock has increased by 51.7% and is now trading at $1.05.
View the best growth stocks for 2024 here
.

When is Sensei Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SNSE earnings forecast
.

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02.

When did Sensei Biotherapeutics IPO?

Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

Who are Sensei Biotherapeutics' major shareholders?

Sensei Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Newtyn Management LLC (6.29%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, John Celebi, Robert Hamilton Pierce and Thomas G Ricks.
View institutional ownership trends
.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNSE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners